N2OFF's 15min chart triggered Bollinger Bands Narrowing, KDJ Death Cross observed.
ByAinvest
Friday, Oct 3, 2025 10:04 am ET1min read
NITO--
Under the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $700,000 and exchange the remaining outstanding shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, representing 40% of N2OFF’s fully diluted capital stock. The sellers will collectively be entitled to 30% of N2OFF’s financing proceeds (capped at $1.6 million) for five years following closing. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis.
N2OFF has committed to financially support MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions.
MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights [1].
Separately, the 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
SPRC--
The 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
SciSparc Ltd. (NASDAQ:SPRC) stock surged 33% on Tuesday following the approval of the proposed acquisition of SciSparc’s majority-owned subsidiary, MitoCareX Bio Ltd., by N2OFF, Inc. (NASDAQ:NITO). This approval was reached during N2OFF’s special meeting on September 25, 2025, marking a significant milestone in the acquisition process.Under the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $700,000 and exchange the remaining outstanding shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, representing 40% of N2OFF’s fully diluted capital stock. The sellers will collectively be entitled to 30% of N2OFF’s financing proceeds (capped at $1.6 million) for five years following closing. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis.
N2OFF has committed to financially support MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions.
MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights [1].
Separately, the 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet